FMP
Advaxis, Inc.
ADXS
PNK
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
0.1 USD
-0.01 (-10%)
Historical Prices
From:
To:
Date
Open
Low
High
Close
Volume
Change
Change %
2025-04-28 10:32:00
0.03
0.03
0.03
0.03
0
-
-
2025-04-28 12:21:00
0.03
0.03
0.03
0.03
0
0
1.05
2025-04-28 12:22:00
0.03
0.03
0.03
0.03
15.78k
0
0
2025-04-28 13:00:00
0.1
0.1
0.1
0.1
0
0.07
197.18
2025-04-28 13:02:00
0.1
0.1
0.1
0.1
4.99k
0
0
2025-04-28 13:03:00
0.1
0.1
0.1
0.1
4.99k
0
0
